Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Summary of immunogenicity in men and women receiving TIV in the immunogenicity set.

From: Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons

Year Antigen Parameter Men
value (95% CI)
N = 482
Women
value (95% CI)
N = 816
Season 1 A/H1N1 % Seroconversion 72 (67, 77) 66 (62, 70)
2005-6   Day 21 GMT 385.9 (334.6, 445.1) 385.1 (344.4, 430.7)
   Day 21% ≥ 40 98 (96, 99) 96 (95, 98)
  A/H3N2 % Seroconversion 85 (81, 89) 85 (82, 88)
   Day 21 GMT 265.4 (231.0, 305.0) 254.4 (227.7, 284.2)
   Day 21% ≥ 40 95 (93, 97) 93 (91, 95)
  B % Seroconversion 83 (79, 87) 81 (77, 84)
   Day 21 GMT 329.6 (291.3, 373.0) 304.6 (275.8, 336.4)
   Day 21% ≥ 40 99 (98, 100) 98 (96, 99)
Season 2 A/H1N1 % Seroconversion 72 (65, 79) 65 (59, 71)
2006-7   Day 21 GMT 414.2 (337.0, 508.9) 318.6 (269.7, 376.3)
   Day 21% ≥ 40 99 (97, 100) 98 (96, 99)
  A/H3N2 % Seroconversion 67 (60, 74) 75 (69, 80)
   Day 21 GMT 141.9 (117.7, 171.1) 168.3 (145.1, 195.3)
   Day 21% ≥ 40 90 (86, 95) 93 (90, 96)
  B % Seroconversion 73 (66, 80) 74 (69, 80)
   Day 21 GMT 290.9 (244.8, 345.7) 296.8 (257.2, 342.5)
   Day 21% ≥ 40 97 (95, 100) 97 (95, 99)
  1. GMT, geometric mean titer